Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a clinical-stage biopharmaceutical company focused on developing abuse-deterrent opioid medicines and treatments for opioid use disorder, utilizing its proprietary MPAR and TAAP platform technologies. The company completed its business combination with a special purpose acquisition company and began trading on Nasdaq in 2021, with operations centered in the specialty pharmaceutical and drug safety sector. The August 2026 8-K filing reflects the company's continued reporting obligations as a publicly traded entity. For comprehensive SPAC deal terms, sponsor details, post-merger performance data, and real-time filing alerts on ENSC and thousands of other SPAC-linked companies, create a free account at SpacDesk.